# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cantor Fitzgerald analyst Kristen Kluska reiterates Disc Medicine (NASDAQ:IRON) with a Overweight and maintains $85 price ta...
Cantor Fitzgerald analyst Kristen Kluska reiterates Disc Medicine (NASDAQ:IRON) with a Overweight and maintains $85 price ta...
HC Wainwright & Co. analyst Douglas Tsao reiterates Disc Medicine (NASDAQ:IRON) with a Buy and maintains $70 price target.
Raymond James analyst Danielle Brill maintains Disc Medicine (NASDAQ:IRON) with a Outperform and raises the price target fro...
Disc Medicine (NASDAQ:IRON) reported quarterly losses of $(1.09) per share which missed the analyst consensus estimate of $(1.0...
Stifel analyst Benjamin Burnett maintains Disc Medicine (NASDAQ:IRON) with a Buy and raises the price target from $71 to $73.
Morgan Stanley analyst Jeffrey Hung maintains Disc Medicine (NASDAQ:IRON) with a Equal-Weight and lowers the price target fr...
BMO Capital analyst Evan Seigerman maintains Disc Medicine (NASDAQ:IRON) with a Outperform and lowers the price target from ...
Stifel analyst Benjamin Burnett maintains Disc Medicine (NASDAQ:IRON) with a Buy and lowers the price target from $104 to $71.